Unfortunately other therapeutic agents targeting PI3K, AKT, or PTEN, including new anti-angiogenic drugs, have failed to significantly improve clinical outcome in patients with HCC [28]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.